Trial reportBone marrow transplantation2006
A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis.
Trial report in Bone marrow transplantation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 63 citations in OpenAlex.
- Allogeneic Transplantation in Advanced Systemic Mastocytosis: A Single-Center Case Series Highlighting Gastrointestinal Toxicity and GvHD Risk.Mediterranean journal of hematology and infectious diseases · 2026Article
- Evolution of mast cell research associated with the Laboratory of Allergic Diseases, 1985-2022: Summary of the 2023 NIAID Symposium.The Journal of allergy and clinical immunology · 2025Review
- Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.Cancers · 2022Review
- Treatment of Indolent and Advanced Systemic Mastocytosis.Mediterranean journal of hematology and infectious diseases · 2022Review
- [Spectrum of gene mutations and clinical features in adult acute myeloid leukemia with normal karyotype].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Systemic mastocytosis with flushing and hypotension: A case report and literature review.Experimental and therapeutic medicine · 2021Article
- Article
- Pharmacological treatment options for mast cell activation disease.Naunyn-Schmiedeberg's archives of pharmacology · 2016Review
- Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Mastocytosis.Immunology and allergy clinics of North America · 2014Review
- An adult patient with systemic mastocytosis and B-acute lymphoblastic leukemia.Case reports in medicine · 2014Article
- Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation.Bone marrow transplantation · 2013Article
- Diagnosis and treatment of mast cell disorders: practical recommendations.Sao Paulo medical journal = Revista paulista de medicina · 2013Review
- Eosinophilic myeloproliferative disorders.Hematology. American Society of Hematology. Education Program · 2011Review
- [Systemic mastocytosis--definition of an internal disease].Medizinische Klinik (Munich, Germany : 1983) · 2010Review
- Advanced mast cell disease: an Italian Hematological Multicenter experience.International journal of hematology · 2008Article
- Mast cells and mastocytosis.Blood · 2008Review
- Mastocytosis: advances in diagnosis and treatment.Current allergy and asthma reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Systemic mastocytosis (SM) is a disease characterized by tissue infiltration of neoplastic mast cells originating from hematopoietic stem cells. Patients with advanced SM have a poor prognosis, and there is no mast cell ablative therapy available for most patients who carry an activating point mutation in the c-kit gene. We report results of a prospective study evaluating the safety, engraftment, and possibility of inducing a graft-versus-mast cell (GvMC) effect after allogeneic nonmyeloablative hematopoietic cell transplantation (HCT) from an HLA-identical sibling. Three patients with advanced SM were transplanted. All achieved complete donor T cell chimerism followed by clinical evidence for GvMC effect. However, all patients experienced disease progression with the longest response duration of 39 months. The GvMC effect can be observed after nonmyeloablative HCT with limited efficacy. Effective cytoreductive therapy prior to HCT may be required for long-term disease control and cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.